Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial

Highlights • We evaluated safety of an investigational HSV vaccine in girls aged 10–17 years. • Serious adverse events (SAEs) were evaluated over 12 months (primary objective). • SAE rates did not differ significantly between the HSV vaccine and control groups. • A clinically acceptable safety profile was observed for the HSV vaccine overall. • The HSV vaccine was immunogenic in this study group, regardless of HSV serostatus.